Brukinsa Європейський Союз - словенська - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Ciqorin 25 mg mehke kapsule Словенія - словенська - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ciqorin 25 mg mehke kapsule

teva pharma b.v. - ciklosporin - kapsula, mehka - ciklosporin 25 mg / 1 kapsula - ciklosporin

Ciqorin 100 mg mehke kapsule Словенія - словенська - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ciqorin 100 mg mehke kapsule

teva pharma b.v. - ciklosporin - kapsula, mehka - ciklosporin 100 mg / 1 kapsula - ciklosporin

Lojuxta Європейський Союз - словенська - EMA (European Medicines Agency)

lojuxta

amryt pharmaceuticals dac - lomitapide - hiperholesterolemija - sredstva za spreminjanje lipidov - lojuxta je navedena kot dodatek k dieti low‑fat in drugimi lipid‑lowering zdravili z ali brez citofereza nizko gostoto lipoproteinov (ldl), pri odraslih bolnikih s homozigotno družinsko hiperholesterolemijo (hofh). genetske potrditev hofh, je treba pridobiti, kadar je to mogoče. druge oblike primarne hyperlipoproteinaemia in sekundarne vzroke hypercholesterolaemia (e. nephrotic sindrom, hipotiroidizem) mora biti izključena.